Health
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A – Science
SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the…
Abstract
SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (IC90 = 0.88 nM) 27.5-fold more potent than remdesivir against SARS-CoV-2 in vitro, with limited toxicity in cell culture. Through the use of a drug resistant mutant, we show that the antiviral activity of plitidepsin against SARS-CoV-2…
-
Noosa News16 hours agoTeenage boy crashes into Ipswich home, left fighting for life in hospital
-
Noosa News24 hours agoAustralian exporters fear Donald Trump’s tariffs will trigger global recession
-
General22 hours agoUN special envoy Julie Bishop makes first trip to Myanmar after earthquake
-
General20 hours agoNZ PM wants united trade bloc-EU response to tariffs